A Study of PHST001 in Advanced Solid Tumors (NCT06840886)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). In Phase 1b cohort expansions, the study will focus on participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma. The study's primary objective is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 monotherapy and in combination with chemotherapy as well as assess the anti-tumor activity of PHST001 and chemotherapy in Phase 1b.
Who can join: Review the eligibility criteria below.
Location: Precision NextGen Oncology & Research Center — Beverly Hills, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Precision NextGen Oncology & Research Center — Beverly Hills, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Stanford University School of Medicine — Palo Alto, California
- Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- University of Chicago Medical Center — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- START Center for Cancer Research - Midwest — Grand Rapids, Michigan
- START Center for Cancer Research - Long Island New York — Lake Success, New York
- Mount Sinai — New York, New York
- Duke Cancer Institute — Durham, North Carolina
- Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville, Tennessee
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
- START Center for Cancer Research - Texas — Fort Worth, Texas
- MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology - Dallas — Irving, Texas
- START Center for Cancer Research - San Antonio — San Antonio, Texas
- University of Texas (UT) Health — San Antonio, Texas
- NEXT Oncology - Virginia — Fairfax, Virginia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.